Banham N D G (1998) Fatal venlafaxine overdose . Medical Journal of Australia169: 445–448 (letter)
2.
Blythe D , Hackett P L (1999) Cardiovascular and neurological toxicity of venlafaxine . Human & Experimental Toxicology18: 309–313
3.
Buckley N A , McManus P R (2002) Fatal toxicity of serotonergic and other antidepressant drugs: analysis of United Kingdom mortality data . British Medical Journal325: 1332–1333
4.
Carnes C A , Pickworth K K , Votolato N A , Roman S V (2004) Elevated defibrillation threshold with venlafaxine therapy . Pharmacotherapy24: 1095–1098
5.
Colbridge M G , Volans G N (1999) Venlafaxine in overdose – experience of the national poisons information service (London centre) . Journal of Toxicology. Clinical Toxicology37: 383-383
6.
Committee on Safety of Medicines (2005a) Analysis of Yellow Card reports for venlafaxine. At http://www.mhra.gov.uk (accessed 1 December 2005)
7.
Committee on Safety of Medicines (2005b) Analysis of Yellow Card reports for paroxetine. At http://www.mhra.gov.uk (accessed 1 December 2005)
8.
Danjou P , Hackett D (1995) Safety and tolerance profile of venlafaxine . International Clinical Psychopharmacology, 10: 15–20
9.
Dierick M (1996) An open-label evaluation of the long-term safety of oral venlafaxine in depressed elderly patients . Annals of Clinical Psychiatry8: 169–178
10.
Duff G (2004) Safety of selective serotonin reuptake inhibitor antidepressants. At http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/safetymessages/SSRI_Letter_061204.pdf (accessed 7th December 2005)
11.
Duff G (2006) Updated prescribing advice for venlafaxine (Efexor/Efexor XL). At www.nhra.gov.uk (accessed 7th June 2006)
12.
Egberts A C , Lenderin , A W , De Koning F H , Leufkens H G (1997) Channelling of three newly introduced antidepressants to patients not responding satisfactorily to previous treatment . Journal of Clinical Psychopharmacology17: 149–155
13.
Fantaskey A , Burkhart K K (1995) A case report of venlafaxine toxicity . Journal of Toxicology. Clinical Toxicology33: 359–361
14.
Feighner J P (1995) Cardiovascular safety in depressed patients: focus on venlafaxine . Journal of Clinical Psychiatry56: 574–579
15.
Harrison C L , Ferrier N , Young A H (2004) Tolerability of high-dose venlafaxine in depressed patients . Journal of Psychopharmacology18: 200–204
16.
Henry J A , Antao C A (1992) Suicide and fatal antidepressant poisoning . European Journal of Medicine1: 343–348
17.
Kelly C A , Dhaun N , Laing W J , Strachan F E , Good A M , Bateman D N (2004) Comparative toxicity of citalopram and the newer antidepressants after overdose . Journal of Toxicity. Clinical Toxicity42: 67–71
18.
Khalifa M , Daleau P , Turgeon J (1999) Mechanism of sodium channel block by venlafaxine in guinea pig ventricular myocytes . Journal of Pharmacology and Experimental Therapeutics291: 280–284
19.
Kokan L , Dart R C (1996) Life-threatening hypotension from venlafaxine overdose . Annals of Emergency Medicine27: 815-815
20.
Lessard E , Yessine M A , Hamelin B A , O'Hara G , LeBlanc J , Turgeon J (1999) Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans . Pharmacogenetics9, 435–443
21.
Mazur J E , Doty J D , Krygiel A S (2003) Fatality related to a 30g venlafaxine overdose . Pharmacotherapy23: 1668–1672
22.
Mendels J , Johnston R , Mattes J , Riesenberg R (1993) Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study . Psychopharmacology Bulletin29: 169–174
23.
MHRA (2006) Venlafaxine (EFEXOR) summary of basis for regulatory position. At www.mhra.goc.uk (accessed 7th June 2006)
24.
Mines D , Hill D , Yu H , Novelli L (2005) Prevalence of risk factors for suicide in patients prescribed venlafaxine, fluoxetine, and citalopram. Pharmacoepidemiology and Drug Safety. Published online DOI: 10.1002/pds.1095
25.
Morgan O , Griffiths C , Baker A , Majeed A (2004) Fatal toxicity of antidepressants in England and Wales, 1993–2002 . Health Statistics Quarterly23: 18–24
26.
National Institute for Clinical Excellence (2004) Clinical Guideline 23; Depression: management of depression in primary and secondary care. At http://www.nice.org.uk
27.
National Prescribing Centre (2005a) The management of depression in primary care . MeRec Briefing31: 1–8
28.
National Prescribing Centre (2005b) The management of depression in primary care . MeRec Briefing31: 1–8
29.
Nutt D J (2005) Death by tricyclic: the real antidepressant scandal?J of Psychopharmacology19(2): 123-123
30.
Ostrom M , Eriksson A , Thrson J , Spigset O (1996) Fatal overdose with citalopram . Lancet348: 339–340
31.
Parsons A T , Anthony R M , Meeker J E (1996) Two fatal cases of venlafaxine poisoning . Journal of Analytical Toxicology20: 266–268
32.
Peano C , Leikin J B , Hanashiro P K (1997) Seizures, ventricular tachycardia and rhabdomyolysis as a result of ingestion of venlafaxine and lamotrigine . Annals of Emergency Medicine30: 704–708
33.
Poirier M F , Boyer P (1999) Venlafaxine and paroxetine in treatment resistant depression. Double-blind, randomised comparison . British Journal of Psychiatry175: 12–16
34.
Reznik I , Rosen Y , Rosen B (1999) An acute ischaemic event associated with the use of venlafaxine: a case report and proposed pathophysiological mechanisms . Journal of Psychopharmacology13: 193–195
35.
Rudolph R L , Derivan A T (1996) The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database . Journal of Clinical Psychopharmacology, 16, 54S-61S .
36.
Shrivastava R K , Cohn C , Crowder J , Davidson J , Dunner D , Feighner J , Kiev A , Patrick R (1994) Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression . Journal of Clinical Psychopharmacology14: 322–329
37.
Smith D , Dempster C , Glanville J , Freemantle N , Anderson I (2002) Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis . British Journal of Psychiatry180: 396–404
38.
Thase M , Entsuah R , Rudolph R L (2001) Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors . British Journal of Psychiatry178: 234–241
39.
Thomas A , Taylor D (2003) Evaluating the relationship of high-dose venlafaxine prescribing to treatment-resistant depression . Psychiatric Bulletin27: 93–95
40.
Whyt , I M , Dawson A H , Buckley N A (2003) Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants . Quarterly Journal of Medicine96: 369–374
